Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has upgraded Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announced a $30 price target.
August 07, 2023 | 11:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics has been upgraded from Hold to Buy by Maxim Group with a new price target of $30.
The upgrade from Hold to Buy by Maxim Group indicates a positive outlook for Vistagen Therapeutics. The new price target of $30 suggests that the analyst expects the stock price to rise in the short term. This could potentially attract more investors, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100